Andrew Goldberg Buys Shares of TARS
Andrew Goldberg purchased 2,954 shares of TARS on June 12, 2026.
Key Points
- Andrew Goldberg acquired 2,954 shares of TARS on June 12, 2026, reflecting insider confidence.
- TARS shares traded at $61.85, with institutional investors like Deep Track Capital and Janus Henderson Group adjusting their positions.
- Analysts from firms like HC Wainwright & Co. and Oppenheimer maintain 'buy' ratings with targets as high as $105.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Andrew Goldberg recently bought 2,954 shares of TARS on June 12, 2026. This transaction, not under a prearranged plan, adds to the insider activity surrounding the company.
Other Institutional Activity in TARS
Deep Track Capital, LP increased its holdings in TARS by 595,966 shares, bringing its total to 3.6 million shares valued at approximately $252.54 million. Meanwhile, BlackRock, Inc. reduced its position by 237,945 shares, ending with about 3.55 million shares worth $249.22 million. RTW Investments, LP made a smaller increase of 10,705 shares, now holding 3.35 million shares valued at $234.72 million. Janus Henderson Group PLC also grew its stake by 310,638 shares, totaling 2.24 million shares with a value of $157.22 million.
Tarsus Pharmaceuticals, Inc. Stock Down 13.8%
Shares of TARS traded at $61.85. The company's stock has been the subject of various institutional moves, indicating continued interest from large investors.
$TARS stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 4, 2026, HC Wainwright & Co. reiterated its 'buy' rating for TARS with a price target of $88. Oppenheimer maintained a 'buy' rating on February 25, 2026, with an ambitious target of $105. Guggenheim also maintained its 'buy' rating with a $90 target on the same day.
Bottom Line
Insider buying by Andrew Goldberg suggests confidence in TARS at a time of active institutional trading. Investors often watch such trades closely to gauge market sentiment. As always, remember that insider activity is backward-looking and may not reflect the current position.
Get Tarsus Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TARS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.